AssayIndex
Rollups

Compounds

66 compounds catalogued with hand-authored analytical properties — formula, monoisotopic mass, retention on the index reference method, characteristic impurities and degradation pathways — and the distribution of every result the index holds for each. 63 of them carry at least one record.

66 catalogued63 with records9 classes6,584 reports
CompoundClassMonoisotopic DaRT (min)ReportsBatchesSuppliersMedian %IQR ppSpec %Difficulty
SemaglutideIncretin4111.052418.427681152698.890.9697.01.25
TirzepatideIncretin4810.410319.867501052798.550.9697.01.40
BPC-157Tissue-repair1418.70939.62510852699.160.9798.00.90
RetatrutideIncretin4728.487120.71492742398.370.8696.51.55
TB-500Tissue-repair887.49647.86268572399.530.5798.50.85
CJC-1295 (no DAC)Growth-hormone3365.740212.86220381999.090.7498.01.05
SemaxNeuroactive813.35417.06216311799.460.7798.50.85
GHRP-6Growth-hormone872.44468.44206362099.540.5199.00.85
IpamorelinGrowth-hormone711.38568.24204422099.470.7999.00.80
PT-141 (Bremelanotide)Melanocortin-receptor1024.52429.52152311999.380.9798.50.90
MK-677 (Ibutamoren mesylate)Non-peptide624.218113.86143251999.490.6998.50.80
L-Glutathione (reduced)Short307.08384.28129261899.331.0798.50.90
SS-31 (Elamipretide)Metabolic639.38568.94124241599.530.9998.50.85
CJC-1295 with DACGrowth-hormone3644.974814.62121271698.950.8197.51.20
IGF-1 LR3Growth-hormone9105.241216.92118171498.281.0895.01.60
GHRP-2Growth-hormone817.42759.06110181499.280.8099.00.85
MOTS-cMetabolic2173.091810.42105201599.131.3198.01.00
SelankNeuroactive751.44026.42102241999.590.6199.00.80
AOD-9604Metabolic1815.867211.289615999.290.7598.00.95
ARA-290Tissue-repair1189.60968.7291171499.420.5998.00.90
EpitalonShort390.13874.6290151199.560.9199.00.80
LiraglutideIncretin3748.963117.2888191599.000.8497.51.15
N-Acetyl Semax AmideNeuroactive854.38067.6288171199.350.9398.50.85
5-Amino-1MQNon-peptide285.99675.4278141099.450.4498.00.85
Melanotan IIMelanocortin-receptor1023.54029.8477191399.420.6598.50.90
Kisspeptin-10Melanocortin-receptor1301.63009.147611899.280.7298.50.90
GHK-CuTissue-repair401.10246.18729998.560.8797.01.20
SurvodutideIncretin4764.512120.147010998.381.3296.51.45
Enclomiphene citrateNon-peptide597.213016.4470161199.440.8798.50.90
KPVTissue-repair342.22675.2469131199.640.8299.00.75
SermorelinGrowth-hormone3355.724512.4258141099.060.7398.01.10
CagrilintideIncretin3961.321816.745411998.690.9796.51.35
ExenatideIncretin4183.937014.92497798.980.7198.01.05
HexarelinGrowth-hormone886.46028.924810999.591.1099.00.85
OxytocinHypothalamic1006.43657.92486699.810.3198.50.95
NAD+Non-peptide663.10914.164412999.281.4997.01.00
Thymosin α1Tissue-repair3106.549312.724310999.400.7697.51.10
AfamelanotideMelanocortin-receptor1645.847410.864310699.060.9898.00.95
PEG-MGFGrowth-hormone7894.000017.24428897.750.7692.01.70
MGFGrowth-hormone2886.511711.62377799.290.8997.51.10
Humanin (HNG)Metabolic2685.315312.14358799.120.6697.51.05
GonadorelinHypothalamic1181.58258.68336699.120.8598.50.85
MazdutideIncretin4912.640819.42298698.140.7996.51.40
LeuprolideHypothalamic1208.66129.44295499.280.5898.50.90
L-CarnosineShort226.10663.72266699.580.6399.00.85
TriptorelinHypothalamic1310.62489.72244499.410.6398.50.90
DesmopressinHypothalamic1068.42658.14223398.830.8798.50.95
DihexaNeuroactive504.331212.24226599.630.2398.50.85
SLU-PP-332Non-peptide410.130015.28223398.880.5498.00.90
AdipotideMetabolic4095.623812.74225498.581.1496.01.35
TesamorelinGrowth-hormone5131.927615.44185498.290.3897.01.30
LL-37Tissue-repair4490.426514.36174498.900.7996.51.30
VilonShort275.14813.94174499.650.7899.00.80
GlucagonIncretin3480.619413.61153399.200.4198.01.10
PramlintideIncretin3947.106413.94152299.100.4797.51.15
ThymulinTissue-repair873.37166.62152299.270.2998.01.00
IGF-1 DES (1-3)Growth-hormone7365.718815.86153299.121.1595.01.55
VIPTissue-repair3324.814612.98122297.560.5897.51.15
PemvidutideIncretin4679.401420.3685598.250.6396.01.45
P21Neuroactive805.397010.4281199.230.3998.00.85
ThymalinShort——711n<3—99.01.80
PinealonShort418.18124.8632299.93—99.00.80
Follistatin-344Growth-hormone——111n<3—98.01.90
GIP (1-42)Incretin4980.516315.84000n<3—97.01.20
Larazotide acetateTissue-repair749.40727.44000n<3—98.50.85
SetmelanotideMelanocortin-receptor1116.47009.28000n<3—98.01.00
12 compounds

Incretin analogues and co-agonists

GLP-1, GIP and glucagon receptor agonists, including the lipidated long-acting analogues and the dual and triple co-agonists.

Semaglutide

NN9535 · C187H291N45O59

4111.05 DaRT 18.42difficulty 1.25
reports768
median %98.89
spec %97.0

Tirzepatide

LY3298176 · C225H348N48O68

4810.41 DaRT 19.86difficulty 1.40
reports750
median %98.55
spec %97.0

Retatrutide

LY3437943 · C221H342N46O68

4728.49 DaRT 20.71difficulty 1.55
reports492
median %98.37
spec %96.5

Liraglutide

NN2211 · C172H265N43O51

3748.96 DaRT 17.28difficulty 1.15
reports88
median %99.00
spec %97.5

Survodutide

BI 456906 · C220H340N50O67

4764.51 DaRT 20.14difficulty 1.45
reports70
median %98.38
spec %96.5

Cagrilintide

AM833 · C194H310N54O61

3961.32 DaRT 16.74difficulty 1.35
reports54
median %98.69
spec %96.5

Exenatide

exendin-4 · C184H282N50O60S

4183.94 DaRT 14.92difficulty 1.05
reports49
median %98.98
spec %98.0

Mazdutide

IBI362 · C226H352N50O70

4912.64 DaRT 19.42difficulty 1.40
reports29
median %98.14
spec %96.5

Glucagon

GCG (1-29) · C153H225N43O49S

3480.62 DaRT 13.61difficulty 1.10
reports15
median %99.20
spec %98.0

Pramlintide

AC137 · C171H267N51O53S2

3947.11 DaRT 13.94difficulty 1.15
reports15
median %99.10
spec %97.5

Pemvidutide

ALT-801 · C218H336N48O66

4679.40 DaRT 20.36difficulty 1.45
reports8
median %98.25
spec %96.0

GIP (1-42)

glucose-dependent insulinotropic polypeptide · C226H347N57O67S

4980.52 DaRT 15.84difficulty 1.20
reports0
median %—
spec %97.0
08817626492.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=196.00–96.25 %: n=196.25–96.50 %: n=596.50–96.75 %: n=1296.75–97.00 %: n=2097.00–97.25 %: n=3997.25–97.50 %: n=6297.50–97.75 %: n=11397.75–98.00 %: n=19798.00–98.25 %: n=23798.25–98.50 %: n=29898.50–98.75 %: n=29298.75–99.00 %: n=31199.00–99.25 %: n=28399.25–99.50 %: n=21899.50–99.75 %: n=12699.75–100.00 %: n=123median 98.65 Purity (% area) Reports
Figure. Class-wide purity distribution, 2,338 records across 12 compounds. Median 98.65 % area against a class specification of 97.0 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Metabolic and mitochondrial peptides

Mitochondrial-derived peptides, growth-hormone fragments and peptidomimetics acting on metabolic targets.

SS-31 (Elamipretide)

elamipretide · C32H49N9O5

639.39 DaRT 8.94difficulty 0.85
reports124
median %99.53
spec %98.5

MOTS-c

mitochondrial open reading frame of the 12S rRNA type-c · C101H152N28O22S2

2173.09 DaRT 10.42difficulty 1.00
reports105
median %99.13
spec %98.0

AOD-9604

hGH fragment 176-191 (Tyr-) · C78H123N23O23S2

1815.87 DaRT 11.28difficulty 0.95
reports96
median %99.29
spec %98.0

Humanin (HNG)

HN · C119H182N30O32S

2685.32 DaRT 12.14difficulty 1.05
reports35
median %99.12
spec %97.5

Adipotide

FTPP · C190H332N60O43

4095.62 DaRT 12.74difficulty 1.35
reports22
median %98.58
spec %96.0
020406092.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=297.25–97.50 %: n=597.50–97.75 %: n=1197.75–98.00 %: n=1598.00–98.25 %: n=1898.25–98.50 %: n=2598.50–98.75 %: n=4198.75–99.00 %: n=3099.00–99.25 %: n=4099.25–99.50 %: n=6799.50–99.75 %: n=5799.75–100.00 %: n=71median 99.27 Purity (% area) Reports
Figure. Class-wide purity distribution, 382 records across 5 compounds. Median 99.27 % area against a class specification of 98.0 %. Same fixed 92–100 % domain as every other purity histogram here.
10 compounds

Tissue-repair and immunomodulatory peptides

Short to medium linear peptides marketed for tissue repair, mucosal integrity and immune modulation.

BPC-157

Body Protection Compound 157 · C62H98N16O22

1418.71 DaRT 9.62difficulty 0.90
reports510
median %99.16
spec %98.0

TB-500

thymosin β4 fragment (17-23) · C39H69N9O14

887.50 DaRT 7.86difficulty 0.85
reports268
median %99.53
spec %98.5

ARA-290

cibinetide · C50H83N15O18

1189.61 DaRT 8.72difficulty 0.90
reports91
median %99.42
spec %98.0

GHK-Cu

copper tripeptide-1 · C14H22CuN6O4

401.10 DaRT 6.18difficulty 1.20
reports72
median %98.56
spec %97.0

KPV

Lys-Pro-Val · C16H30N4O4

342.23 DaRT 5.24difficulty 0.75
reports69
median %99.64
spec %99.0

Thymosin α1

Tα1 · C129H215N33O55

3106.55 DaRT 12.72difficulty 1.10
reports43
median %99.40
spec %97.5

LL-37

human cathelicidin LL-37 · C205H340N60O53

4490.43 DaRT 14.36difficulty 1.30
reports17
median %98.90
spec %96.5

Thymulin

serum thymic factor · C35H55N9O17

873.37 DaRT 6.62difficulty 1.00
reports15
median %99.27
spec %98.0

VIP

vasoactive intestinal peptide · C147H238N44O42S

3324.81 DaRT 12.98difficulty 1.15
reports12
median %97.56
spec %97.5

Larazotide acetate

AT-1001 · C34H55N9O10

749.41 DaRT 7.44difficulty 0.85
reports0
median %—
spec %98.5
07314621992.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=196.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=297.25–97.50 %: n=797.50–97.75 %: n=897.75–98.00 %: n=2198.00–98.25 %: n=5298.25–98.50 %: n=6298.50–98.75 %: n=10398.75–99.00 %: n=10899.00–99.25 %: n=14499.25–99.50 %: n=16399.50–99.75 %: n=16799.75–100.00 %: n=259median 99.32 Purity (% area) Reports
Figure. Class-wide purity distribution, 1,097 records across 10 compounds. Median 99.32 % area against a class specification of 98.0 %. Same fixed 92–100 % domain as every other purity histogram here.
13 compounds

Growth-hormone axis peptides

GHRH analogues, growth-hormone secretagogues, IGF-1 variants and conjugates.

CJC-1295 (no DAC)

mod-GRF (1-29) · C152H252N44O42

3365.74 DaRT 12.86difficulty 1.05
reports220
median %99.09
spec %98.0

GHRP-6

growth hormone releasing hexapeptide · C46H56N12O6

872.44 DaRT 8.44difficulty 0.85
reports206
median %99.54
spec %99.0

Ipamorelin

NNC 26-0161 · C38H49N9O5

711.39 DaRT 8.24difficulty 0.80
reports204
median %99.47
spec %99.0

CJC-1295 with DAC

CJC-1295 DAC · C165H269N47O46

3644.97 DaRT 14.62difficulty 1.20
reports121
median %98.95
spec %97.5

IGF-1 LR3

Long R3 IGF-1 · C400H625N111O116S9

9105.24 DaRT 16.92difficulty 1.60
reports118
median %98.28
spec %95.0

GHRP-2

pralmorelin · C45H55N9O6

817.43 DaRT 9.06difficulty 0.85
reports110
median %99.28
spec %99.0

Sermorelin

GRF (1-29) · C149H246N44O42

3355.72 DaRT 12.42difficulty 1.10
reports58
median %99.06
spec %98.0

Hexarelin

examorelin · C47H58N12O6

886.46 DaRT 8.92difficulty 0.85
reports48
median %99.59
spec %99.0

PEG-MGF

pegylated mechano growth factor · conjugate (24-mer + 5 kDa mPEG)

7894.00 DaRT 17.24difficulty 1.70
reports42
median %97.75
spec %92.0

MGF

mechano growth factor · C121H200N42O37

2886.51 DaRT 11.62difficulty 1.10
reports37
median %99.29
spec %97.5

Tesamorelin

TH9507 · C221H366N72O67S

5131.93 DaRT 15.44difficulty 1.30
reports18
median %98.29
spec %97.0

IGF-1 DES (1-3)

DES(1-3)IGF-1 · C317H508N92O95S7

7365.72 DaRT 15.86difficulty 1.55
reports15
median %99.12
spec %95.0

Follistatin-344

FS-344 · recombinant protein (344 aa)

mass not defineddifficulty 1.90
reports1
median %—
spec %98.0
05811617492.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=195.75–96.00 %: n=296.00–96.25 %: n=396.25–96.50 %: n=196.50–96.75 %: n=196.75–97.00 %: n=897.00–97.25 %: n=1297.25–97.50 %: n=1397.50–97.75 %: n=3097.75–98.00 %: n=3998.00–98.25 %: n=5698.25–98.50 %: n=7898.50–98.75 %: n=10498.75–99.00 %: n=12399.00–99.25 %: n=18399.25–99.50 %: n=15999.50–99.75 %: n=17999.75–100.00 %: n=205median 99.17 Purity (% area) Reports
Figure. Class-wide purity distribution, 1,197 records across 13 compounds. Median 99.17 % area against a class specification of 98.0 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Melanocortin-receptor peptides

Cyclic and linear melanocortin agonists, plus the kisspeptin decapeptide.

PT-141 (Bremelanotide)

bremelanotide · C50H68N14O10

1024.52 DaRT 9.52difficulty 0.90
reports152
median %99.38
spec %98.5

Melanotan II

MT-II · C50H69N15O9

1023.54 DaRT 9.84difficulty 0.90
reports77
median %99.42
spec %98.5

Kisspeptin-10

KP-10 · C63H83N17O14

1301.63 DaRT 9.14difficulty 0.90
reports76
median %99.28
spec %98.5

Afamelanotide

NDP-α-MSH · C78H111N21O19

1645.85 DaRT 10.86difficulty 0.95
reports43
median %99.06
spec %98.0

Setmelanotide

RM-493 · C49H68N18O9S2

1116.47 DaRT 9.28difficulty 1.00
reports0
median %—
spec %98.0
023466992.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=297.75–98.00 %: n=1098.00–98.25 %: n=1498.25–98.50 %: n=2398.50–98.75 %: n=2598.75–99.00 %: n=2899.00–99.25 %: n=4899.25–99.50 %: n=6599.50–99.75 %: n=5199.75–100.00 %: n=82median 99.36 Purity (% area) Reports
Figure. Class-wide purity distribution, 348 records across 5 compounds. Median 99.36 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Hypothalamic and posterior-pituitary hormones

GnRH analogues and the nonapeptide hormones, several of which have pharmacopoeial monographs.

Oxytocin

Pitocin · C43H66N12O12S2

1006.44 DaRT 7.92difficulty 0.95
reports48
median %99.81
spec %98.5

Gonadorelin

GnRH · C55H75N17O13

1181.58 DaRT 8.68difficulty 0.85
reports33
median %99.12
spec %98.5

Leuprolide

leuprorelin · C59H84N16O12

1208.66 DaRT 9.44difficulty 0.90
reports29
median %99.28
spec %98.5

Triptorelin

D-Trp6-LHRH · C64H82N18O13

1310.62 DaRT 9.72difficulty 0.90
reports24
median %99.41
spec %98.5

Desmopressin

DDAVP · C46H64N14O12S2

1068.43 DaRT 8.14difficulty 0.95
reports22
median %98.83
spec %98.5
012243692.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=097.75–98.00 %: n=098.00–98.25 %: n=198.25–98.50 %: n=898.50–98.75 %: n=1498.75–99.00 %: n=1899.00–99.25 %: n=2199.25–99.50 %: n=2299.50–99.75 %: n=3299.75–100.00 %: n=40median 99.45 Purity (% area) Reports
Figure. Class-wide purity distribution, 156 records across 5 compounds. Median 99.45 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Neuroactive and cognitive peptides

ACTH-derived and tuftsin-derived peptides, lipidated tripeptide amides and adamantylated fragments.

Semax

Met-Glu-His-Phe-Pro-Gly-Pro · C37H51N9O10S

813.35 DaRT 7.06difficulty 0.85
reports216
median %99.46
spec %98.5

Selank

TP-7 · C33H57N11O9

751.44 DaRT 6.42difficulty 0.80
reports102
median %99.59
spec %99.0

N-Acetyl Semax Amide

NASA · C39H54N10O10S

854.38 DaRT 7.62difficulty 0.85
reports88
median %99.35
spec %98.5

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · C27H44N4O5

504.33 DaRT 12.24difficulty 0.85
reports22
median %99.63
spec %98.5

P21

P021 · C36H55N9O12

805.40 DaRT 10.42difficulty 0.85
reports8
median %99.23
spec %98.0
033669992.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=297.75–98.00 %: n=198.00–98.25 %: n=898.25–98.50 %: n=2698.50–98.75 %: n=2698.75–99.00 %: n=4099.00–99.25 %: n=5499.25–99.50 %: n=6599.50–99.75 %: n=9999.75–100.00 %: n=115median 99.48 Purity (% area) Reports
Figure. Class-wide purity distribution, 436 records across 5 compounds. Median 99.48 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.
6 compounds

Short bioregulator peptides

Di-, tri- and tetrapeptide bioregulators, plus the thiol tripeptide glutathione and the dipeptide carnosine.

Epitalon

epithalon · C14H22N4O9

390.14 DaRT 4.62difficulty 0.80
reports90
median %99.56
spec %99.0

L-Carnosine

β-alanyl-L-histidine · C9H14N4O3

226.11 DaRT 3.72difficulty 0.85
reports26
median %99.58
spec %99.0

Vilon

Lys-Glu · C11H21N3O5

275.15 DaRT 3.94difficulty 0.80
reports17
median %99.65
spec %99.0

Thymalin

thymus polypeptide extract · polypeptide mixture

mass not defineddifficulty 1.80
reports7
median %—
spec %99.0

Pinealon

Glu-Asp-Arg · C15H26N6O8

418.18 DaRT 4.86difficulty 0.80
reports3
median %99.93
spec %99.0
023466992.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=197.50–97.75 %: n=297.75–98.00 %: n=1098.00–98.25 %: n=998.25–98.50 %: n=1298.50–98.75 %: n=1598.75–99.00 %: n=2699.00–99.25 %: n=3099.25–99.50 %: n=4499.50–99.75 %: n=3799.75–100.00 %: n=79median 99.41 Purity (% area) Reports
Figure. Class-wide purity distribution, 265 records across 6 compounds. Median 99.41 % area against a class specification of 99.0 %. Same fixed 92–100 % domain as every other purity histogram here.
5 compounds

Non-peptide adjuncts

Small molecules and nucleotide cofactors submitted alongside peptides. Different specification, different methods, same index.

5-Amino-1MQ

5-amino-1-methylquinolinium · C10H11N2+ · I−

286.00 DaRT 5.42difficulty 0.85
reports78
median %99.45
spec %98.0

Enclomiphene citrate

enclomiphene · C26H28ClNO · C6H8O7

597.21 DaRT 16.44difficulty 0.90
reports70
median %99.44
spec %98.5

NAD+

nicotinamide adenine dinucleotide · C21H27N7O14P2

663.11 DaRT 4.16difficulty 1.00
reports44
median %99.28
spec %97.0

SLU-PP-332

ERR pan-agonist SLU-PP-332 · C22H22N2O4S

410.13 DaRT 15.28difficulty 0.90
reports22
median %98.88
spec %98.0
025507592.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=497.75–98.00 %: n=698.00–98.25 %: n=1598.25–98.50 %: n=1898.50–98.75 %: n=1898.75–99.00 %: n=3699.00–99.25 %: n=4299.25–99.50 %: n=6399.50–99.75 %: n=6999.75–100.00 %: n=86median 99.43 Purity (% area) Reports
Figure. Class-wide purity distribution, 357 records across 5 compounds. Median 99.43 % area against a class specification of 98.5 %. Same fixed 92–100 % domain as every other purity histogram here.